Annual Conference
Our flagship global event — three days of cross-specialty pediatric education in Copenhagen, 3–5 December 2026, for clinicians, researchers, and policymakers.
The Excellence in Pediatrics Institute (EIPI) is a not-for-profit association built for the physicians and child healthcare professionals on the frontline of care. We advance their knowledge and skills, connect them across specialties and borders, and bring the latest science and innovation directly into their everyday practice — so that every clinician is equipped to give infants, children and adolescents the best possible care.
Our mission is to strengthen the physicians who care for children. We provide holistic cross-specialty education, help clinicians recognize what is too often missed, and bridge the gap between emerging science and daily practice. By putting knowledge, skills, and innovation directly into the hands of frontline pediatricians, we improve the health and well-being of children and adolescents worldwide.
From our flagship annual conference to focused education and advocacy programs, these are the initiatives through which EIP advances prevention, early diagnosis, and lifelong health for children worldwide.

Our flagship global event — three days of cross-specialty pediatric education in Copenhagen, 3–5 December 2026, for clinicians, researchers, and policymakers.

Expert-led training that helps pediatricians and GPs recognize rare diseases early and refer in time — with Learning Zones for MPS, MLD, Alpha-mannosidosis, and CLN2.

A science-to-policy initiative turning prevention evidence into action across every stage of life, from childhood immunization to healthy aging.

Connecting early-career clinicians with experienced mentors through structured learning, shared knowledge, and a supportive professional community.
Stay informed with the latest updates from the Excellence in Pediatrics Institute.
Stay informed with the latest reports, strategic updates, and prevention-focused insights from the LifeCourse Prevention Initiative and its global partners.
.webp)
This policy report presents a comprehensive, evidence-based review and policy recommendations for RSV prevention in infants and young children. It draws on epidemiological data, clinical trial results, real-world effectiveness studies and the lived experiences of families affected by RSV to present a comprehensive picture of the burden this virus imposes and the strategies available to reduce it, also addressing the important and under-recognized interaction between RSV and pneumococcal disease.

The report brings together evidence, policy perspectives, and practical experience from leading experts across public health, clinical practice, social science, civil society, and policy, all focused on a critical question: why do vaccination inequities persist, and what will it take to fix them? The answer that emerged is clear: Vaccination inequities are not accidents. They are predictable, patterned, and preventable outcomes of how systems are designed, measured, and experienced.
.webp)
This report presents findings from a survey of primary care providers and pediatricians, examining the burden of RSV across diagnosis, treatment, and prevention. It reveals rising case severity compared with prior seasons, underuse of diagnostic testing, and inconsistent vaccination recommendations. The report closes with recommendations to strengthen diagnostic capacity, standardize treatment protocols, and expand education for frontline providers.
.webp)
This report presents findings from a survey of 198 pediatric healthcare professionals that examines why children go unvaccinated in mixed-income communities. It distinguishes outright vaccination refusal driven by mistrust, sociocultural beliefs, and low health literacy from adherence issues such as missed appointments, which stem from logistical and economic barriers. The report closes with targeted recommendations for healthcare systems and practices to improve equity.

This report sets out the case for protecting all infants and adults rather than high-risk groups alone: it examines the strain on hospitals and ICUs, the link between RSV and antimicrobial resistance, the family transmission cycle that fuels epidemics, and the socioeconomic toll on families, before weighing prevention approaches from maternal immunization to long-acting monoclonal antibodies.

With flu coverage historically low after COVID, sustaining influenza vaccination has become a test of health-system resilience. This report examines three themes: protecting and expanding influenza vaccine funding, sharpening the messaging and weighing new vaccine technology against the 75% coverage target, and lifting uptake among the sub-groups that matter most — pregnant women, children, people with chronic conditions and healthcare professionals.

RSV drives pneumococcal disease and shapes lung function into adulthood. Why its lasting burden is the strongest case for early universal prevention.

Progressive neurodegenerative disorders in children are rare but often diagnosed too late. This webinar explores why earlier recognition matters for clinicians.

Think Rare expands to CLN2 (Batten Disease), a rare neurodegenerative disease in young children, with new live webinars coming up.

Free vaccines don't guarantee equal access. Why child poverty drives vaccination inequity, and why reducing it is a prerequisite.

The tools for RSV prevention work; coverage decides the impact. Multi-country evidence on reaching every infant, from the 2025 LifeCourse Prevention Summit.

When communities are engaged as partners, vaccination programs work better. Insights from the 2025 LifeCourse Summit on co-design, engagement, and equity.
A 60-minute expert-led webinar on distinguishing CLN2 disease from more common pediatric neurological, developmental, and behavioral presentations. Led by Dr. Marina Trivisano and Dr. Pasquale Striano, the session covers reassessment frameworks, differential diagnosis, escalation, and referral pathways, offering practical guidance for pediatric neurologists, general pediatricians, and primary care clinicians to recognize red-flag symptom combinations and move toward timely testing and specialist referral.
A 60-minute expert-led webinar addressing the challenge of recognizing progressive neurodegeneration in children, a significant but under-recognized clinical burden that is frequently diagnosed late. Led by Prof. Nicole Wolf, Dr. Serena Gasperini, and Prof. Samuel GrΓ¶schel, the session focuses on identifying early clinical red flags, distinguishing progressive neurodegeneration from other pediatric presentations, and applying a structured diagnostic approach using case models from MLD and MPS III.
A 40-minute expert-led webinar on recognizing the early signs of CLN2 disease, a rare and rapidly progressive neurodegenerative condition within the neuronal ceroid lipofuscinoses (NCLs) spectrum. Led by Dr. Paul Gissen, the session helps clinicians identify early symptom patterns, recognize disease progression and clustering cues, and understand when concern should trigger escalation, referral, and genetic testing.
A 60-minute webinar on newborn screening and sibling testing for Metachromatic Leukodystrophy (MLD), featuring family perspectives and expert guidance on NBS rationale, multi-tier confirmation pathways, early intervention, and Norway's rollout. Designed to help paediatric teams improve communication, speed referrals, and standardise care for NBS-positive infants and at-risk siblings.
This 60-minute webinar addresses a critical unmet need: educating pediatricians on the link between Alpha-Mannosidosis (AM) and immune system dysfunction. Led by Prof. Susanna Esposito and Prof. Giacomo Biasucci, the session explores recurring infections, diagnostic challenges, overlaps with immunodeficiencies, and the integration of immunological monitoring into multidisciplinary care. The goal is to optimize patient management by improving recognition, diagnosis, and treatment pathways.
This 60-minute webinar, part of our Series 3 program, focuses on advancing the diagnosis and treatment of Alpha-Mannosidosis (AM). Led by Dr Julia B. Hennermann and Dr Sarah Haupenthal, the session explores how enzyme replacement therapy (ERT) plays a central role in managing AM, alongside the equally important dimension of psychological support. The programme highlights how combining medical treatment with mental health care and family support can optimise outcomes and improve patient well-being.
Excellence in Pediatrics brings together renowned pediatric specialists, researchers, and educators from around the world. Through groundbreaking research, shared clinical practices, and mentorship, our faculty and expert contributors inspire and support the next generation of child healthcare professionals.
Join a global community of child healthcare professionals committed to advancing child healthcare.